AIMS

AIMS

(1) Cardiology APSAC (Anisoylated Plasminogen Streptokinase Activator Complex) Intervention Mortality Study. A trial comparing 1-year mortality in acute MI patients randomized to APSAC or placebo
Conclusions At 30 days, 6% of APSAC patients had died vs. 12% of placebo patients; at 1 year, the mortality rates were 11% and 18%, and major AMI complications were less common in APSAC patients; ethical considerations terminated the trial early because of the 47% decrease in the 30-day mortality in APSAC patients; APSAC reduced acute MI mortality by 54% over the placebo controls in those age 60–70, and by 34% in those < age 60, if given within 6 hrs
Number of patients 1,004 patients; 254 were added later Selection criteria Sx of acute MI, age 70, 30 min pain, 1 mm ST elevation in 2 limb leads or 2 mm in 2 precordial leads
(2) Abnormal Involuntary Movement Scale